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Increased levels of the repressor element 1/neuron restrictive
silencer element (RE1/NRSE) silencing activity promoter, and a
consequent reduction in the transcription of many RE1/NRSE-
bearing neuronal genes, including brain-derived neurotrophic
factor (BDNF), have been demonstrated in Huntington disease
(HD) and represent one possible effector of its selective neuro-
nal vulnerability. Restoring the expression levels of neuronal
genes in diseased neurons therefore seems to be an attractive
therapeutic approach. To this end, we have developed a cell-
based reporter assay for monitoring RE1/NRSE silencing activ-
ity and validated it by genetically inactivating the RE1/NRSE or
pharmacologically stimulating global transcription. In a pilot
compound screen, we identified three closely related structural
analogues that up-regulate reporter expression at low nanomo-
lar concentrations, and follow-up studies have shown that they
efficaciously increase endogenous BDNF levels in HD cells.
Moreover, one of the compounds increases the viability of HD
cells. Our findings suggest a new avenue for the development of
drugs for HD and other neurodegenerative disorders based on
thepharmacological up-regulationof the productionof theneu-
ronal survival factor BDNF and of other RE1/NRSE-regulated
neuronal genes.
Huntington disease (HD)4 is an inherited dominant neuro-
degenerative disorder for which there is no effective treatment.
Since the discovery that its genetic cause is a polyglutamine
expansion in the novel protein huntingtin (1), extensive efforts
have been made to find its underlying mechanisms and poten-
tial therapeutic targets.
A number of pathogenic mechanisms have been considered
so far, which indicates that more than one target should be
investigated to reach a positive therapeutic effect (2–4). Most
of these targets have been identified by looking at diseasemech-
anisms triggered by gain of function defects caused by mutant
huntingtin (5), andwe and other groups have hypothesized that
diminished wild-type huntingtin function may also contribute
to the pathogenesis of HD (6). This suggests that a complemen-
tary approach based on identifying compounds that mimic
wild-type huntingtin activity should be considered: the admin-
istration of novel compounds capable of restoring wild-type
huntingtin function, together with drugs reducingmutant hun-
tingtin toxicity, may be an optimal therapeutic strategy.
The repressor element 1/neuron restrictive silencer element
(RE1/NRSE) was the first example of an affected target of wild-
type huntingtin activity to be discovered and is a silencer of
gene expression (7–9). Bioinformatic studies indicate thatmore
than 1000 neuronal genes in the human genome bear an RE1/
NRSE sequence in their promoters (10, 11), of which brain-
derived neurotrophic factor (BDNF) is particularly interesting,
because it is a pro-survival factor for the striatal neurons that
die inHD.We have previously shown that wild-type huntingtin
stimulates BDNF gene transcription (12) by retaining in the
cytoplasm the transcription factor that binds and activates the
silencing transcription factor/neuron-restrictive silencer factor
(REST/NRSF) sites involved in the regulation of RE1/NRSE and
located inside BDNF promoter II (13). The inactivation of RE1/
NRSE sites allows BDNF gene transcription (13, 14). Mutant
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huntingtin is less capable of recruiting REST/NRSF in the cyto-
plasm, which leads to its pathological translocation to the
nucleus and increased occupancy of its cognate RE1/NRSE
genomic loci (13, 14). In HD, the occupied RE1/NRSE silences
transcription fromRE1/NRSE-regulated genes, thus contribut-
ing to neuronal dysfunction (13, 14).
Interest in compounds acting on a transcriptional system
that supports the transcription of the BDNF gene (among oth-
ers) is sustained by the fact that positive outcomes have been
observed in HDmodels after increasing BDNF levels by means
of transplanting cells engineered to overexpress BDNF into a
chemical model of HD (15) or delivering BDNF via gene ther-
apy (16, 17). Transgenic overexpression of BDNF in the cere-
bral cortex can delay the progression of disease phenotypes in
the R6/1 HD mouse model carrying the first 63 amino acids of
mutant human huntingtin protein (18), and the genetic reduc-
tion of BDNF in the same R6/1 mice causes a worse phenotype
(19). Furthermore, these findings are paralleled by the fact that
mice lacking cortical BDNF show a hind limb clasping pheno-
type similar to that observed in mouse models of HD (20).
Finally, it has beenmore recently demonstrated that cystamine
improves the HD phenotype in mice by enhancing BDNF
release from the Golgi compartment in brain cells (21).
We here describe the development of the first cell-based
assay designed to screen for compounds that are potentially
capable of restoring the loss of wild-type huntingtin function in
RE1/NRSE-mediated gene transcription by identifying genetic
and chemical RE1/NRSE modulators. We used this assay to
identify some small molecules that inhibit RE1/NRSE activity
and then assessed their efficacy on molecular and phenotype
parameters in HD cellular models.
EXPERIMENTAL PROCEDURES
Transcription Factor and Reporter Gene Constructs—The
RE1/NRSEbdnf-LUC reporter construct was constructed using
the enhanced luciferase reporter gene pGL3-promoter (Pro-
mega, Madison,WI) as a backbone. A 300-bp portion of the rat
BDNF promoter exon II containing the RE1/NRSE sequence
was obtained from the BDNF"II CAT construct (41), and sub-
cloned into the Xho-HindIII digested pGL3-promoter from
which SV40 was excised. The same cloning strategy was used
for the mutated RE1/NRSEbdnf-LUC. The 300-bp insert was
obtained from the BDNFI"IImut CAT construct (42). The
mutated nucleotides in themutatedRE1/NRSE are described in
Timmusk et al. (42). The DN:REST and REST/NRSF (22, 10)
expression constructs were kindly provided by Noel J. Buckley,
University of Leeds, UK.
Cell Cultures, Engineering, and Antibiotic Selection—ST14A
and STHdhQ111/HdhQ111 cells were grown in high glucose Dul-
becco’smodified Eagle’smedium supplementedwith 10% heat-
inactivated fetal bovine serum at 33 °C in a 5%CO2 atmosphere
(43). For the transient transfection experiments, the harvested
ST14A cells were resuspended in electroporation medium
(Dulbecco’s modified Eagle’s medium) at a density of 625,000
cells/ml, and 400 !l of the cell suspension was put into an elec-
troporation cuvette together with plasmids (see “Results” for
the amounts). The cells were electroporated using a BTX
ElectroSquare PoratorTM ECM 830 at 160 V for 30 ms and
one pulse, after which they were diluted in complete medium
and plated in 24-well plates.
To obtain stable clones, 8 !g of the RE1/NRSEbdnf-LUC
reporter construct and 2!g of pLXSP for puromycin resistance
were delivered to one million neural cells. After electropora-
tion, the cells were plated in 100-mm Petri dishes and a selec-
tion medium containing 3 !l/ml puromycin was applied 24 h
later. After 15 days of selection pressure, 25 single clones were
transferred to 24-well plates and expanded. The subcloneswere
tested for basal luciferase activity and, in a second step, those
that were positive were electroporated with DN:REST (5!g) to
detect subclones expressing a functional and responsive RE1/
NRSEbdnf. For DN:REST infection, 109 plaque-forming
units/ml of virus particles were used to infect 145,000 cells.
Chemicals and Chemical Exposure—A panel of compounds
of interest to test in the developed assay was assembled. Small
molecules known to be pan-HDAC inhibitors (TSA or SAHA)
and other transcriptional activators were included, in addition
to entities that mightmodulate BDNF pathway and expression.
CRF, CRF antagonist, forskolin, azacitidine-A, TSA, SAHA,
and tranylcipromine were purchased from Sigma. Compounds
2, 18, and 19 and amonafide and its derivatives were purchased
from Chembridge Corp. (San Diego, CA). The compounds
were dissolved in Me2SO and kept in 10 mM stock solutions
before being added at the indicated doses to the cells plated in
on the day before. ThemRNAor proteins were collected for the
different experiments at the indicated time points.
Determination of Luciferase Expression—In transient exper-
iments, Renilla was used to normalize the transfection effi-
ciency data, and a Dual Luciferase Reporter Assay System was
used according to the manufacturer’s protocol (Promega).
Renilla and firefly luciferase activities were determined using
theVeritasMicroplate Luminometer (Promega), counting each
sample for 8 s. The results are given as firefly/Renilla relative
light units (RLUs).
Alternatively, after the addition of luciferin as a substrate
(Beetle Luciferin, Promega), firefly luciferase activity was deter-
mined using the luminometer and is given as RLUs in relation
to protein content, as assessed using a bicinchoninic acid assay
(Pierce).
Gene Expression Analyses—Three independent room tem-
perature reactions were set up for each RNA stock of 1 !g of
total RNA preparations, and gene expression was assessed by
means of real-time PCR. The analyses were made in triplicate
for each of the genes to obtain replicates for statistical analysis.
We used an iCycler Thermal Cycler with a multicolor real-
time PCR detection system (Bio-Rad). All of the reactions were
performed in a total volume of 25!l, containing 25 ng of cDNA,
50 mM KCl, 20 mM Tris-HCl, pH 8.4, 0.2 mM dNTPs, 25
units/ml iTaq DNA polymerase, 3 mM MgCl2, 10 nM SYBR
Green I fluorescein, stabilizers (iQTM SYBR Green Supermix-
Bio-Rad), and 0.2 !M of forward and reverse primers.
The amplification cycles for total BDNF consisted of an ini-
tial 10-min denaturing cycle at 95 °C, followed by 40 cycles of
10 s at 95 °C, 10 s at 56 °C, and 20 s at 72 °C. Fluorescence was
quantified during the 56 °C annealing step, and product forma-
tion was confirmed by means of a melting curve analysis (55–
94 °C). The amounts of target gene mRNA were normalized to
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a reference gene ("-actin) amplified following the same proto-
col. The primer sequences were: BDNF-F, 5!-GAT GAG GAC
CAG AAG GTT CG-3!; BDNF-R, 5!-GAT TGG GTA GTT
CGG CAT TG-3!; "-actin-F, 5!-AGT GTG ACG TTG ACA
TCC GTA-3!; and "-actin-R, 5!-GCC AGA GCA GTA ATC
TCC TTC T-3! (F, forward; R, reverse).
The amplification cycles for synapsin I and M4 muscarinic
receptor consisted of an initial 3-min denaturing cycle at 95 °C,
followed by 40 cycles of 30 s at 95 °C, 30 s at 58 °C, and 30 s at
72 °C. Fluorescence was quantified during the 60 °C annealing
step, and product formationwas confirmed bymeans of amelt-
ing curve analysis (55–94 °C). The primer sequences were: syn-
apsin I-F, 5!-TTT TTGGGGGAC TTG ACA TC-3!; synapsin
I-R, 5!-AGT TCC ACG ATG AGC TGC TT-3!; M4 muscari-
nic-F, 5!-GGA ACC TCT GGC TTG TTC C-3!; M4 muscari-
nic-R, 5!-CAG ACT GAT TGG CTG AGC TG-3!.
The amplification cycles for E2F1 consisted of an initial
10-min denaturing cycle at 95 °C, followed by 40 cycles of 15 s at
95 °C and 1 min at 60 °C. Fluorescence was quantified during
the 60 °C annealing step, and product formationwas confirmed
by means of a melting curve analysis (55–94 °C). The primer
sequences were: E2F1-F, 5!-CCC GCC GGT GAA ACG-3!;
E2F1-R, 5!-GCC TCT GCC CCG GAA T-3!.
The amplification cycles for REST/NRSF consisted of an ini-
tial 3-min denaturing cycle at 95 °C, followed by 45 cycles of 30 s
at 95 °C, 30 s at 60 °C, and 30 s at 72 °C. Fluorescence was quan-
tified during the 60 °C annealing step, and product formation
confirmed by a melting curve analysis (55–94 °C). The primer
sequences were: REST/NRSF-F, 5!-CGAACTCACACAGGA
GAA CG-3!; REST/NRSF-R, 5!-GAG GCC ACA TAA TTG
CAC TG-3!. All the amounts of target gene mRNA were nor-
malized to a reference gene ("-actin) according to a previous
study (44).
ELISA Assay—Cell lysates were prepared in lysis buffer con-
sisting of glycerol 10%, 25 mM Tris HCl, pH 7.5, 150 mM NaCl,
TritonX-100 1%, 5mMEDTA, 1mMEGTA supplementedwith
1:100 of Protease Inhibitor Mixture (Sigma). The samples were
homogenized, sonicated, and centrifuged (Biofuge, 15 min at
4 °C at maximum speed), and the supernatants were collected
and stored at #80 °C. The samples were assayed for BDNF
using an ImmunoAssay System (Promega) as described by the
manufacturer. The proteins were quantified by means of a
bicinchoninic acid protein assay (Pierce) before loading.
Cell Viability Assay—80,000 cells per well were plated in
triplicate into 24-well plates. After 24-h incubation at 33 °C in
5% CO2, the cultures were washed with Hanks’ balanced salt
solution, and the medium was replaced by serum-deprived
medium and then incubated at 37 °C. At the indicated time
points, the cells were exposed to 3-(4,5-dimethylthiazol-2-phe-
nyl)-2,5-diphenyltetrazolium bromide (Sigma-Aldrich), and
themitochondrial release of formazanwas quantified at 560 nm
after incubation at 37 °C for 1 h.
Immunocytochemistry—4500 STHdhQ111/HdhQ111 cells were
plated in 96-well Cellomics plates, coated with poly-lysine, and,
after adhesion, exposed to the selected compound. At the indi-
cated time points, the cells were fixed in paraformaldehyde 4%
for 15min,washedwith 1$phosphate-buffered saline and then
permeabilized with 0.5% Triton X-100 in 1$ phosphate-buff-
ered saline. They were blocked for 1 h at room temperature in
1$ phosphate-buffered saline, 5% nonfat milk, and 5% goat
serum. The cells were exposed to primary antibody (1:500) rab-
bit polyclonal anti-REST (Upstate) for 1 h at room temperature,
followed by the goat anti-rabbit FluoroLink Cy2 (Amersham
Biosciences) secondary antibody (1:500) for 2 h. The nuclei
were stained blue with DAPI. Automatic image capture and
analysis were performed using a Cellomics Array Scan IV
(Thermo Fisher) with the Cytoplasm to Nucleus Translocation
BioApplication. For the BrdUrd incorporation study,
STHdhQ111/HdhQ111 cells were exposed to stress stimuli in the
presence or absence of compound 18. BrdUrd incorporation
was performed over the last 24 h, and the cells were fixed with
paraformaldehyde 4% for 15 min and permeabilized with 0.2%
Triton X-100 in phosphate-buffered saline for 5 min at room
temperature. After DNA denaturation, the cells were stained
using anti-BrdUrd monoclonal antibody (BD Biosciences). For
DNA staining, fixed cells were incubated with DAPI. A total of
200 cells was counted for each sample.
Statistical Analysis—Bonferroni’s test or an ANOVA t test
were used as indicated to evaluate the statistical significance of
the results.
RESULTS
Development of the RE1/NRSEbdnf Luciferase Reporter
Assay—We initially evaluated the functioning of the RE1/
NRSEbdnf luciferase construct and its responsiveness to REST/
NRSF.
ST14A neural cells, which are known to express endogenous
REST/NRSF (13), were transiently transfected with the
reporter construct and a dominant negative REST/NRSF con-
struct (DN:REST) (22). The latter consists of the DNA binding
domain of REST/NRSF, but lacks the repressor domain, and
was expected to attenuate REST/NRSF binding to RE1/
NRSEbdnf within the luciferase reporter and increase luciferase
activity. Forty-eight hours after transfection, there was a pro-
portional increase in luciferase activity with increasing doses of
DN:REST in comparison with untransfected cells or cells
treated with an empty vector (Fig. 1A), thus indicating that
DN:REST overexpression attenuates endogenous REST/NRSF
binding to RE1/NRSEbdnf in a dose-dependent manner. When
co-transfected with RE1/NRSEbdnf luciferase, REST/NRSF
counteracted the luciferase expression induced by DN:REST
(Fig. 1A, light gray column).
Consistently, when present in the promoter controlling the
reporter (mRE1/NRSEbdnf-LUC), a specific mutation in the
RE1/NRSE sequence abolished the effect of DN:REST (Fig. 1B).
It is also worth noting that mRE1/NRSEbdnf -LUC transfection
gave rise to a stronger luciferase signal than RE1/NRSEbdnf
because of the lack of the silencing activity of mutant RE1/
NRSEbdnf (Fig. 1B, third versus first column).We therefore con-
cluded that the RE1/NRSEbdnf luciferase reporter is functional
and specifically responsive to REST/NRSF transcription factor.
Generation and Genetic Validation of the Stable DiaNRSELuc8
Reporter Cell Line—To obtain stable cell subclones, the ST14A
neural cell line was co-transfected with RE1/NRSEbdnf lucifer-
ase andpLXSP vector. After antibiotic selection, 25 puromycin-
resistant subclones were isolated, and the basal expression of
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the transgene was evaluated by means of a luciferase assay; 13
subclones were discarded because of the decrease in luciferase
activity over multiple passages.
The remaining subclones were transiently transfected with
DN:REST or an empty vector, and their luciferase activity was
tested to select subclones stably expressing a functional and
responsive RE1/NRSEbdnf luciferase reporter. 8 of the 12 clones
showed no more than a 1.5-fold increase in luciferase expres-
sion, whichwe thoughtmight be due to effects of the surround-
ing chromatin at the transgene integration sites. However,
DN:REST significantly increased luciferase activity in the
remaining four clones, and we selected the one with the best
signal-to-background ratio for further characterization. Fig. 1C
shows that this clone (designated DiaNRSELuc8) specifically
responds to DN:REST infection with a 6-fold increase in lucif-
erase activity.
Pharmacological Evaluation of DiaNRSELuc8 Cell-based
Assay—AsREST/NRSF recruits HDACs and acts as a repressor
through chromatin remodeling (23, 24), the assay response was
tested in the presence of the known transcriptional activators:
pan-HDAC inhibitors TSA and SAHA.
In particular, when DiaNRSELuc8 cells were exposed to TSA
at concentrations of up to 300 nM, there was a dose-dependent
increase in luciferase activity (Fig. 1D). The effect of TSA indi-
cates that HDAC activity is required for the repression of RE1/
NRSEbdnf by REST/NRSF, and that the RE1/NRSEbdnf within
the luciferase reporter is responsive to an HDAC inhibitor. For
this reason, we selected TSA as the reference compound for
further assay development.
After scaling down the assay to 96 wells, we calculated the Z!
factor, a dimensionless measure of the quality of a high-
throughput screening assay that considers the mean signal and
standard deviation from positive and negative controls (25).
The calculated Z! factor value from 20 independent experi-
ments in which DiaNRSELuc8 cells were exposed to 75 nM of
TSA for 72 h was 0.81 % 0.12, thus indicating the reliability of
the assay.
The basis for the transcriptional response of the developed
assay was evaluated in a pilot drug screening study of a panel of
selected compounds. In the search for a de-repressor of tran-
scription, we first used compounds that are known to possess
this activity. We included a DNA-demethylating agent, azaciti-
dine-A, which activates gene transcription by reducing the sta-
bility of silencing signals, and amonafide and its structurally
FIGURE 1. RE1/NRSEbdnf within a luciferase construct is responsive to
REST/NRSF. A, ST14A cells were transiently co-transfected with the RE1/
NRSEbdnf luciferase construct and the indicated amount of DN:REST; after
48 h, there was a dose-dependent increase in luciferase activity (Bonferroni’s
test). The presence of exogenous REST/NRSF competes with DN:REST, thus
decreasing reporter induction (light gray column). Experiments were per-
formed in triplicate; the data are shown as firefly/Renilla RLUs in relation to
controls (black column). *, p& 0.05; **, p& 0.01 versus the immediately lower
dose. B, ST14A cells were transiently co-transfected with the RE1/NRSEbdnf
luciferase construct bearing a mutated RE1/NRSE (mRE1/NRSFbdnf-LUC) and
DN:REST; after 48 h, there was no increase in luciferase activity, thus confirm-
ing that the induction observed in the presence of RE1/NRSFbdnf-LUC is spe-
cifically due to RE1/NRSFbdnf. The data are shown as firefly/Renilla RLUs in
relation to controls (RE1/NRSFbdnf-LUC transfected cells, first black column).
The experiments were performed in triplicate; **, p& 0.01, Bonferroni’s test.
Genetic and chemical validation of the DiaNRSELuc8 clonal cell line. C, when
theDiaNRSELuc8 subclonewas infectedwithDN:RESTadenoviral supernatant,
therewas a 5.5-fold increase in luciferase activity 48h after infection. Thedata
are shown as firefly RLUs/!g of protein in relation to controls (uninfected
cells, black column). D, when the DiaNRSELuc8 subclone was exposed to
increasingamountsof TSA (anHDAC inhibitor that is effectiveatnanomolar con-
centrations in vitro), there was a dose-dependent increase in luciferase activity;
the concentrationof 75nM was selected for further assaydevelopment. Thedata
areshownasfireflyRLUs/!gofprotein inrelationtocontrols (untreatedcells)and
are theaverageof three independentexperiments. *,p&0.05; **,p&0.01versus
the immediately lower dose, Bonferroni’s test.
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similar derivatives of the C91 series, which have previously
been identified as increasing transcriptional activity in a
reporter assay of mutant huntingtin knock-in cells in which the
reporter was regulated by six Specificity protein-1 binding sites
(26). Small molecules targeting the cell pathways involved in
regulating BDNF expressionwere also chosen, in particular for-
skolin, an activator of adenylate
cyclase, because an increase in
cAMP levels enhances BDNF
expression (27). As it is known that
antidepressants also increase BDNF
expression levels (28, 29), we
selected tranylcipromine, a monoa-
mine oxidase inhibitor; and as some
published findings indicate that
CRF stimulates BDNF expression
(30, 31), we included a structural
analogue of known inhibitors of
CRF receptor (32, 33).
DiaNRSELuc8 cells were plated in
96-well dishes and, after adhesion,
exposed to the chemical entities in
triplicate for 72 h, after which lucif-
erase activity was evaluated. The
compounds were initially tested at
0.1, 1, 5, and 10 !M. None of the
compounds positively modulated
reporter activity in our assay, except
for the structural analogue of CRF
receptor inhibitors (referred to as
compound 2 in this report), which
proved to be highly potent although
toxic in the assay. Compound 2 was
further tested in a dose-dependent
experiment at nanomolar concen-
trations, which revealed a corre-
sponding increase in luciferase
activity from the lowest to the high-
est dose (Fig. 2A). Fig. 2B shows the
increase in luciferase activity
induced by 25 nM of compound 2
over time. Given the specificity of
the result, we next tested a peptide-
based CRF receptor agonist and
antagonist, which had no effects on
luciferase expression (RLU/!g:
untreated control 1: CRF, 200 nM
0.91 % 0.02 and 1 !M 0.88 % 0.02;
CRF-antagonist, 200 nM 0.81% 0.01
and 1 !M 0.83 % 0.01) and thus, in
our view, ruled out the CRF-
dependent mechanism of activa-
tion. This conclusion is supported
by recently published data concern-
ing the absence of any effects of CRF
antagonists on BDNF production in
rats (34).
To ensure the specificity of com-
pound 2, which was identified empirically as being capable of
stimulating luciferase expression, we tested some structurally
similar and commercially available analogues. Compounds 18
and 19, whose ability to induce luciferase activity paralleled the
effect observed in the presence of the positive control, TSA 75
nM (Fig. 2C, black column) as observed for compound 2, were
FIGURE 2. Pilot drug screening assay. Luciferase activity in the DiaNRSELuc8 subclone significantly increased
after the administration of the selected compounds. A, representative dose response: **, p& 0.01 versus the
lower dose, Bonferroni’s test; B, time course: **, p& 0.01 versus time 0, ANOVA. The curves are those of com-
pound 2. C, luciferase activity in DiaNRSELuc8 after the administration of 75 nM of compounds 2, 18, or 19. The
data are the average of three independent experiments: **, p & 0.01 versus untreated cells, ANOVA. D, EC50
assessed by reporter activity, and IC50 assessed by MTT assay, describing cell viability 72 h after exposure to the
indicated compounds. Physical/chemical data are shown for the indicated structures.
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then tested in time-course and dose-response experiments and
showed similar profiles to those observed with compound 2
(data not shown). Fig. 2D shows the structures andproperties of
the three compounds, together with the data relating to their
activity (EC50, luciferase activity) and toxicity (IC50, cell viabil-
ity as assessed by MTT assay). To ensure that the apparent
cytotoxicity of the compounds was not interfering with, or
responsible for, transcriptional activation, DiaNRSELuc8 cells
were exposed to 3-nitropropionic acid (5 and 10 nM) or stauro-
sporine (10 nM), which are known to induce cell death in this
neural cell line (35). As shown, neither increased luciferase
activity (supplemental Fig. S1). Further interest in investigating
the novel structural scaffold was aroused by the in silico predic-
tion that compounds 18 and 19 cross the blood-brain barrier.
Secondary Assay—To evaluate
whether the reporter assay can
identify compounds that inhibit the
activity of the endogenous RE1/
NRSE loci, mRNA was collected
from ST14A neural cells exposed to
compounds 2, 18, or 19. Real-time
PCR showed an increase in total
BDNF mRNA after the administra-
tion of all three compounds (Fig. 3,
left), and an ELISA assay in the same
experimental paradigm showed that
the rescue of BDNFmRNAwasmir-
rored by an increase in BDNF pro-
tein levels. The right panel of Fig. 3
shows the intracellular BDNF pro-
tein contentmeasured in cell lysates
collected under basal conditions
(white column), after 72-h exposure
to TSA as positive control (black
column), and in the presence of the
indicated amount of the different
compounds. Bonferroni’s test
showed that the increase in endoge-
nous BDNF transcription and trans-
lation is dose-dependent (p& 0.01).
Compounds 2, 18, and 19 Increase
Synapsin and M4 Muscarinic
Receptor Gene Expression but Do
Not Affect REST/NRSF or E2F1
Gene Transcription—To demon-
strate that the compounds selected
using DiaNRSELuc8 cells can induce
the RE1/NRSE-regulated expres-
sion of genes other than BDNF, syn-
apsin I and M4 muscarinic receptor
expression were evaluated as two of
the known neuronal genes compris-
ing a RE1/NRSE.
ThemRNAcollected fromparen-
tal ST14A cells (exposed to the dif-
ferent compounds using the same
experimental conditions as above)
was retrotranscribed, and the cDNA
was amplified using specific primers for the two genes. The
results (Fig. 4, A and B) showed that exposure to 200 nM of
compounds 2, 18, or 19 led to a statistically significant increase
in synapsin I mRNA expression, and an increase was also
observed in the case of the M4 muscarinic receptor.
To exclude the possibility that the compounds act as broad
transcriptional activators, we analyzed their effects on the
expression of two genes that are not listed among the RE1/
NRSE-regulated genes: REST/NRSF and E2F1. Real-time PCR
(Fig. 4, C and D) revealed a substantial increase in the cells
treated with the SAHA HDAC inhibitor, whereas the REST/
NRSFandE2F1geneswerenotmodulatedbycompoundsatdoses
that are active on RE1/NRSE genes, thus suggesting that the com-
poundsact selectivelyonRE1/NRSE-regulatedgene transcription.
FIGURE 3. Secondary assay: compound effects on endogenous BDNF mRNA and protein levels. ST14A
cells were exposed to the indicated amount of the three compounds, and, after 72 h, BDNF mRNA and protein
levels were evaluated by means of quantitative real-time PCR and ELISA. The left panels show the quantitative
expression of BDNF mRNA in comparison with "-actin (-fold increase in relation to untreated cells); the right
panels show the quantitative evaluations of BDNF protein levels in relation to total protein content (-fold
increase in relation tountreated cells). Thedata are the averageof three independent experiments: **, p& 0.01
versus the immediately lower dose, Bonferroni’s test. A, BDNF mRNA (left) and protein levels (right) after the
administration of compound 2; B, BDNF mRNA (left) and protein levels (right) after the administration of com-
pound 18; C, BDNF mRNA (left) and protein levels (right) after the administration of compound 19.
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Compounds 2, 18, and 19 Restore BDNF mRNA and Protein
Levels in an HD Context—We next tested whether the com-
pounds increased BDNF gene transcription in the presence of
mutant huntingtin using two previously derived neural cell
lines that showed a decrease in BDNF content in comparison
with their control counterparts (12).
In a first step, compounds 2, 18, or 19 were administered to
neural cell lines derived from homozygous mutant huntingtin
knock-in mice in which an expanded CAG has been inserted
into the endogenous mouse Hdh gene (STHdhQ111/HdhQ111)
(36). Fig. 5A shows the ELISA results indicating an '2-fold
increase after treatment with 200 nM of compounds 2 and 18,
whereas 200 nM of compound 19 did not further increase the
1.6-fold increase observed after treating the cells with 50 nM
of the same compound. The selected compounds also
increased BDNF protein content in independent neural cell
lines engineered in such a way as to stably overexpress the
full-length mutant huntingtin protein (35) (Fig. 5B). It is
worth noting that the desired effect is elicited in a mutant
huntingtin context at the same concentration as that which
is active in parental cells.
Compound 18 Rescues Cell Viability in HD Cell Models—
We next evaluated the impact of compound 18 on
STHdhQ111/HdhQ111 cell viability. The cells were exposed to a
stress stimulus (37 °C, serum-deprived medium) in the pres-
ence or absence of nanomolar concentrations of compound 18,
and cell viability was assessed by MTT assay 48 h after treat-
ment. As shown in Fig. 5C, cell viability increased by 17% 6.6%
in the presence of 50 nM compound 18, and an increase was
observed at a dose of as little as 25 nM (Fig. 5C). This increase in
cell number in the compound-treated group was not due to
increased cell proliferation, because the percentage of BrdUrd-
positive cells was not increased by the compound (Fig. 5D).
Compounds 2, 18, and 19 Do Not Affect REST/NRSF
Translocation—We next attempted to examine STHdhQ111/HdhQ111
cells immunocytochemically in the presence or absence of dif-
ferent doses of compounds 2, 18, or 19 at different time points
(4, 8, 12, 24, 48, and 72 h) using an antibody specifically recog-
nizing the transcription factor REST/NRSF. At each time point,
the nuclear and cytoplasmic levels of REST/NRSF were quan-
tified using the Cellomics Cytoplasm to Nucleus Translocation
BioApplication. This experiment did not reveal any change in
the translocation of REST/NRSF induced by the treatments
(data not shown), thus suggesting that othermechanisms at the
RE1/NRSE sites may inhibit the activity of the silencer in HD
cells exposed to the compounds.
DISCUSSION
The drug screening assay described in this report is based on
a regulatory DNA sequence (the RE1/NRSE silencer within the
BDNF promoter), whose silencing activity is aberrantly
enhanced in HD, because increased binding of its cognate tran-
scription factor REST/NRSF reduces the transcription of
BDNF and other RE1/NRSE-controlled neuronal genes. TheFIGURE4.Thecompoundsaffect synapsin I andM4muscarinicRE1/NRSE-
regulated genes but not non-RE1/NRSE-regulated genes such as REST/
NRSFandE2F1. ST14A cellswere exposed to the indicated concentrations of
the three selected compounds for 72 h, and the mRNA levels of synapsin I (A)
and M4 muscarinic receptor (B) (two known RE1/NRSE-regulated genes), and
E2F1 (C) and NRSF/REST (D) (two non-RE1/NRSE-regulated genes) were eval-
uated by means of quantitative real-time PCR. The graphs show quantitative
expression in comparison with"-actin (-fold increase in relation to untreated
cells). The data are the average of three independent experiments: **, p &
0.01 versus the immediately lower dose, ANOVA.
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REST/NRSF phenotype is related to reduced normal hunting-
tin activity, because genetic modifications of huntingtin level
leading to its overexpression or depletion respectively decrease
or increase REST/NRSF binding.
We have developed a stable recombinant neural cell sub-
clone (DiaNRSELuc8) bearing a reporter construct in which
luciferase activity is controlled by a 300-bp portion of the BDNF
promoter containing the RE1/NRSE. The engineered cell line
shows correct functional coupling of the REST/NRSF tran-
scription factor to the RE1/NRSEbdnf within the reporter con-
struct, as assessed by the transfection of REST and its dominant
negative form, and was therefore used for pilot drug screening.
Three of the tested compounds proved to be capable of inhib-
iting the silencing activity of RE1/NRSEbdnf within the reporter,
thus leading to an increase in reporter activity. Remarkably, this
effect occurs at low nanomolar concentrations. Moreover, a
secondary assay showed that the identified compounds also
inhibit RE1/NRSEbdnf within the endogenous BDNF locus. The
significant increase in BDNF mRNA levels is mirrored by
higher BDNF protein levels and, because this effect is also elic-
ited in a mutant huntingtin context, it is possible that the com-
pounds may trigger the same effect in the human pathology.
Our assay was developed on the basis of a molecular mecha-
nism that has been elucidated in HD models and confirmed in
autoptic tissue (12, 13) and allows the identification of com-
pounds that are active on RE1/NRSE-regulated genes.
The rationale for this drug-screening system, which is sup-
ported by the known positive effect of genetic or pharmacolog-
ical BDNF administration inHDmousemodels, is enhanced by
the fact that the identified compounds may offer two advan-
tages over BDNF administration. First, they are small mole-
cules, which overcomes the pharmacokinetic problems usually
associated with peptide administration, and, secondly (and
more importantly), their effect goes beyond BDNF rescue,
because they also increase the transcription of other neuronal
genes bearing RE1/NRSE in their promoter, as described here
in the case of synapsin I and M4 muscarinic receptors. The
assay selects compounds that modulate a RE1/NRSE-con-
trolled reporter and are, therefore, active on endogenous RE1/
NRSE-regulated genes, and, because such genes are crucial for
neuronal survival and phenotypic maintenance, finely regu-
lated support of their transcription should have a positive
impact on neuronal activity. This extends the application of the
assay (and perhaps that of the identified compounds) to pathol-
ogies other than HD. The deregulation of REST/NRSF and its
target genes in brain has in fact been demonstrated in a number
of neurodegenerative conditions, including the response to
ischemic stress (37, 38), Down syndrome (39), and somemedul-
loblastomas (40). Our compounds not only increase endoge-
FIGURE 5. Compound administration to mutant huntingtin cells. Com-
pounds 2, 18, and 19 were administered at the indicated concentrations to
mutant huntingtin STHdhQ111/HdhQ111 cells (A) or neural cells stably overex-
pressing mutant huntingtin (B), and, 72 h later, BDNF protein levels were
determined by ELISA assay (-fold increase in relation to untreated cells). The
data are the average of two independent experiments. C, STHdhQ111/HdhQ111
cellswere exposed to a stress stimulus (37 °C, serum-deprivedmedium) in the
presence or absence of the indicateddoses of compound18, and cell viability
was assessedbymeansof theMTTassay, 48hafter treatment. Thegraph shows
a dose-dependent increase in cell survival in the presence of the compound.
The data are the average of three independent experiments: **, p & 0.01,
ANOVA. D, STHdhQ111/HdhQ111 cells exposed to the same experimental condi-
tions as in C were incubated in the presence of 0.3 mg/ml BrdUrd 24 h before
being fixed and then immunocytochemically processed for using an anti-
BrdUrd antibody. The DNA was stained with DAPI, which confirmed an
increase in cell viability in the presence of the compound (black column, per-
centage of DAPI-positive cells versusuntreated sample). However, there were
no statistically significant differences in BrdUrd incorporation (white column,
percentage of BrdUrd versus DAPI-positive cells).
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nous RE1/NRSE-regulated genes and protein expression (as
demonstrated in the secondary assay) but are also active in an
HD cell context, in which they increase cell viability. Further
medicinal chemistry studies will be performed to improve the
activity versus toxicity ratio of the selected compound. Given
the results obtained in cells, the compounds (and/or their
future derivates) will be tested in animals to verify their ability
to rescue from HD molecular and phenotypic impairments.
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